- Home
- FIVE vs IONS Comparison
FIVE vs IONS Comparison
Compare FIVE & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIVE
- IONS
- Stock Information
- Founded
- FIVE 2002
- IONS 1989
- Country
- FIVE United States
- IONS United States
- Employees
- FIVE N/A
- IONS N/A
- Industry
- FIVE Department/Specialty Retail Stores
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- FIVE Consumer Discretionary
- IONS Health Care
- Exchange
- FIVE Nasdaq
- IONS Nasdaq
- Market Cap
- FIVE 6.7B
- IONS 5.9B
- IPO Year
- FIVE 2012
- IONS 1991
- Fundamental
- Price
- FIVE $131.09
- IONS $39.62
- Analyst Decision
- FIVE Buy
- IONS Buy
- Analyst Count
- FIVE 19
- IONS 17
- Target Price
- FIVE $115.94
- IONS $57.59
- AVG Volume (30 Days)
- FIVE 1.7M
- IONS 1.7M
- Earning Date
- FIVE 06-04-2025
- IONS 07-31-2025
- Dividend Yield
- FIVE N/A
- IONS N/A
- EPS Growth
- FIVE N/A
- IONS N/A
- EPS
- FIVE 4.78
- IONS N/A
- Revenue
- FIVE $4,035,191,000.00
- IONS $717,253,000.00
- Revenue This Year
- FIVE $16.13
- IONS $7.98
- Revenue Next Year
- FIVE $9.97
- IONS $16.09
- P/E Ratio
- FIVE $27.32
- IONS N/A
- Revenue Growth
- FIVE 10.71
- IONS N/A
- 52 Week Low
- FIVE $52.38
- IONS $23.95
- 52 Week High
- FIVE $137.30
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- FIVE 66.87
- IONS 75.33
- Support Level
- FIVE $121.11
- IONS $34.78
- Resistance Level
- FIVE $133.33
- IONS $37.54
- Average True Range (ATR)
- FIVE 3.69
- IONS 1.19
- MACD
- FIVE -0.79
- IONS 0.33
- Stochastic Oscillator
- FIVE 65.38
- IONS 85.91
About FIVE Five Below Inc.
Five Below Inc is a specialty value retailer offering merchandise targeted at the tween and teen demographic. The Company's edited assortment of products includes select brands and licensed merchandise. It derives revenue from sales of the Company's merchandise to customers.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.